The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Erik Penser Bank, Tel: +46 8 463 80 00. Erik Penser Bank equity research

Annual Report

  November 29, 2022

Company Presentation

 January 25, 2023
  Quarterly Report 1 22/23, January 25 2023
Preemptive medicine aims to precisely predict the onset and progression of disease and provide therapeutic interventions as early as possible to prevent symptoms and complications. This concept will greatly influence the way autoimmune diabetes is treated. We know that by specifically and safely tackling the underlying cause of the disease and preserving remaining insulin-producing cells, there is a great opportunity to improve the lives of individuals both living with clinically diagnosed Type 1 Diabetes (so called Stage 3 Type 1 Diabetes) as well as...
Our pipeline for autoimmune diabetes is potentially game changing. Focusing on safe and specific interventions that have the promise to realize the true value of preemptive medicine. Spearheaded by Diamyd®, an antigen-specific immunotherapy for individuals carrying a common risk gene (haplotype DR3-DQ2”), provides us with the opportunity to address up to 40 % of the millions of individuals at risk or diagnosed with autoimmune diabetes in the world.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
February 22 − February 25, 2023
ATTD 2023
February 23, 2023
Erik Penser Bank Temadag
vd Ulf Hannelius presenterar på Erik Penser Banks Temadag: Healthcare. Presentationen sänds live kl. 16:30 CET.
February 27 − March 1, 2023
6th Antigen-Specific Immune Tolerance Summit
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of December 30, 2022

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 417 026 12.24 9.42
Lindkvist, Bertil 6 240 000 8.11 6.24
Nordnet Pension 3 550 817 4.62 3.55
Essen-Möller, Anders 556 223 2 813 040 4.38 8.38
Essen-Möller, Maria-Teresa 400 000 963 998 1.77 4.97
Essen-Möller, Jon 400 000 566 087 1.26 4.57
Essenshaw, My 400 000 411 036 1.05 4.41
Hillborg, Erika 400 000 384 304 1.02 4.39
Esssen-Möller, Martin 400 000 355 120 0.98 4.36
Konstruktions o Försäljningsaktiebolag 725 000 0.94 0.73
Remaining shareholders 48 944 288 63.62 48.98
Total 2 556 223 74 370 716 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS